Turnstone to discontinue all clinical studies, explore strategic alternatives
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2025
0mins
Should l Buy ?
Turnstone Biologics Program Discontinuation: Turnstone Biologics has decided to discontinue all clinical studies related to TIDAL-01 and halt further development of the program, while initiating a strategic review process to maximize shareholder value.
Workforce Reduction and Cost Containment: The company is reducing its workforce and implementing cost-containment measures, retaining only essential employees for supporting value-realization during the strategic review.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
